Genome-wide association studies (GWAS) have consistently identified PLCE1 as esophageal squamous cell carcinoma (ESCC) susceptibility gene; however, the functional role of PLCE1 variants remains to be verified. In this study, we performed fine mapping of the PLCE1 region using our previous ESCC GWAS data and identified 33 additional risk variants in this susceptibility locus. Here, we report the functional characterization of a four-nucleotide insertion/deletion variation (rs71031566 C----/CATTT) in PLCE1 that was associated with risk of developing ESCC. We demonstrate for the first time that rs71031566[CATTT] insertion creates a silencer element, repressing PLCE1 transcription via long-range interaction with PLCE1 promoter mediated by OCT-2 binding. PLCE1 is down-regulated in majority of clinical ESCC samples and overexpression of PLCE1 in ESCC cells suppresses cell growth in vitro and in vivo, suggesting a tumor suppressor role of this gene. Therefore, repression of PLCE1 transcription may be the underlying mechanism for the rs71031566[CATTT] variant to be susceptible to ESCC.
Introduction
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide, with almost half of the world's 500 000 new cases each year occurring in China (1) . Three genome-wide association studies (GWAS) and a further joint analysis of these studies (2−5) have identified several loci associated with risk of ESCC in Chinese populations; however, the biological mechanism underlying such associations has scarcely elucidated. Clarifying the functional relevance for the action of susceptibility locus is important in the post-GWAS studies (6) .
The rs2274223 variant in PLCE1 at chromosome 10q23 has consistently shown strongly association with ESCC risk in three independent GWAS (2−4). PLCE1 encodes PLCε1, a member of phospholipase C enzyme family that catalyze hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) to generate inositol-1,4,5-trisphosphate (IP3) and diacylglycerol. IP3 and diacylglycerol are responsible for many cellular processes including proliferation, inflammation, angiogenesis and migration, all of which are hallmarks of cancer development and progression (7, 8) . However, the role of PLCE1 in esophageal tumorigenesis remains to be elucidated. PLCE1 is a large gene that contains 334.4 kilobases (kb) and harbors 32 exons and the reported risk variant is located in exon 26 of PLCE1 resulting in His to Arg amino acid change and might impair PLCε1 activity. However, genetic variants can occur in coding and non-coding regions of a given locus and variants in non-coding regions may affect gene expression (9) , consequently impacting on tumorigenesis and/or cancer progression. Therefore, besides rs2274223, there may be other functional variants that were untyped in the previous GWAS and it also merits deciphering these variants to comprehensively elucidate the effect of PLCE1 on ESCC development.
In the present study, we performed imputation analysis of the PLCE1 locus using our previous GWAS data and identified a novel four-nucleotide insertion-deletion (indel) variation located in intron 22 of PLCE1 associated with susceptibility to ESCC. Biochemical assays and functional analysis demonstrated that this indel variation has substantial impact on the PLCE1 gene expression probably through a long-range regulation mechanism. The insertion allele creates a silencer element and interacts with the transcriptional suppressor OCT2 (also known as POU2F2), resulting in an allele-specific inhibition of PLCE1 expression. Deficiency of PLCE1 expression due to genetic variation might be the underlying mechanism for the variant carriers to be susceptible to ESCC.
Materials and methods

Study populations
The genetic association analysis in this study was an extension of our previous GWAS on ESCC. The recruitment and characteristics of the study subjects were described previously (4) . All ESCC cases were confirmed by histopathological or cytological examination according to the WHO classification. The distributions of select characteristics among cases and controls in the genome-wide discovery and replication stage are shown in Supplementary Table 1, available at Carcinogenesis Online. At recruitment, informed consent was obtained from each subject. This study was approved by the Institutional Review Board of the Chinese Academy of Medical Sciences Cancer Hospital.
Imputation of PLCE1 variants
For fine mapping of genetic variations in PLCE1, we conducted imputation analysis based on the GWAS data of 2031 ESCC cases and 2044 controls genotyped using Affymetrix 6.0 chip (4). We used MACH software to impute ungenotyped markers using the linkage disequilibrium and haplotype information from the 1000 Genomes Project March 2012 release CHB + JPT population as a reference set (NCBI Build 37). We estimated imputation quality by masking 2% of the genotypes at random, and we then imputed these SNPs and compared their values with the original genotypes to estimate genotypic error rates. This comparison of imputed and experimentally derived genotypes in our samples yielded an estimated error rate of 1.46% per allele. After imputation, markers with imputation r 2 < 0.5 and SNPs with minor allele frequency < 1% were excluded from all subsequent analysis. Imputed SNPs were tested for association using PLINK software implementing a logistic regression. Regional association plots and haplotype block plots were generated using snp.plotter package in R.
Genotyping analysis of rs71031566 polymorphism
Genotyping analysis of rs71031566[C----] to [CATTT] polymorphism in this study was accomplished with a TaqMan assay platform (ABI 7900HT system, Applied Biosystems) with the primers and probes shown in Supplementary Table 2, available at Carcinogenesis Online. For genotyping quality control, 20% masked random samples were genotyped twice by different investigators and the concordance was 100%.
Cell lines and cell culture
Human ESCC cell lines were generously provided by Dr. Y. Shimada of Hyogo College of Medicine, Japan. RKO, BxPC-3, H460, H1299 and Hela cells were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences Shanghai Institute of Biochemistry and Cell Biology. All cell lines were characterized by DNA finger printing analysis ad tested for free from mycoplasma infection. All cells were maintained in RPMI1640 medium with 10% fetal bovine serum and were grown without antibiotics in an atmosphere of 5% CO 2 and 37°C.
RNA extraction and quantitative real time-PCR (qRT-PCR) analysis
Total RNA was extracted from cell lines or surgically removed tumors and adjacent normal tissues from 168 individuals with ESCC recruited at Cancer Hospital, Chinese Academy of Medical Science (Beijing sample, N = 80) and Cancer Hospital of Zhejiang Province (Hangzhou sample, N = 88) and then converted to cDNA. qRT-PCR was performed in triplicate using the SYBR Green method on ABI Prism 7900HT real-time PCR system (Applied Biosystems) with the primers (Supplementary Table 2 , available at Carcinogenesis Online). The measurement of individual RNA expression was determined relative to the levels of GAPDH transcript. [CATTT] genotype, respectively. These PLCE1 intronic fragments were then directionally cloned into pGL4.10-E4TATA firefly luciferase expression vector to generate the corresponding enhancer (silencer) reporter plasmids. To examine whether the fragment containing rs71031566[C----] or rs71031566 [CATTT] has different PLCE1 promoter-driving ability, the E4TATA sequence in the plasmid was replaced with PLCE1 promoter (2598 base pairs from −3049 to −451), which was generated by PCR amplification of human genomic DNA. The authenticity of all the constructs was verified by sequencing. All primers used in plasmids construction are shown in Supplementary Table 2, available at Carcinogenesis Online.
Construction of reporter plasmids
Transient transfection and luciferase assays
To examine the effects of rs71031566 or rs12220125 variants, cells were transfected with allele-different reporter constructs. For normalization of luciferase activity, the pBEC22control vector encoding Renilla luciferase was co-transfected. Luciferase activity was determined with the DualLuciferase Reporter System (Promega). For each plasmid construct, three independent transfection experiments were conducted and each had six replicates.
Chromosome conformation capture (3C) assays
3C assays were performed as described (10) Table 2 , available at Carcinogenesis Online). Biotin-labeled oligonucleotides and nuclear protein extracts were incubated for 20 min using the Light Shift Chemiluminescent EMSA kit (Thermo Fisher). For competition assays, unlabeled oligonucleotides at 10-or 100-fold molar excess were added to the reaction mixture before the addition of biotinlabeled probe. Antibody against OCT2 (Abcam, ab33919) was used for super-shift assays. Reaction mixtures were separated by 8% PAGE, and products were detected by Stabilized Streptavidin-Horseradish Peroxidase Conjugate (Thermo Fisher).
Chromatin immunoprecipitation combined quantitative PCR
The cross-linked chromatins prepared from KYSE30 or KYSE150 cells were immunoprecipitated with specific antibody against OCT2 (Abcam, ab33919) or IgG. qPCR was accomplished by using SYBR Green (TaKaRa, RR420A) and the primers targeting PLCE1 promoter region or intron 22 where the rs71031566 polymorphism resides (Supplementary Table 4 , available at Carcinogenesis Online). PCR products were separated on 2% agarose gel and the signals were normalized to inputs. We also carried out chromatin immunoprecipitation assays using cross-linked chromatin extracted from KYSE30 cells with OCT2 knockdown by siRNA (Supplementary Table 5 , available at Carcinogenesis Online). All assays were performed using Chromatin Immunoprecipitation Assay Kit (Millipore, 17-10086).
Expression plasmid construction, lentiviral production and transduction
The expression vector (pcDNA3.1) harboring human OCT2 cDNA (NM_002698.4) was purchased from GeneCopoeia. Human PLCE1 transcript 1 cDNA (NM_016341.3, Origene) and PLCE1 shRNA (Supplementary Table 6 , available at Carcinogenesis Online) were cloned into pLenti-C-Myc-DDK-IRES-Neo (Origene) or pSIH1-H1-Puro (System Biosciences) lentiviral vector, respectively. To generate ESCC cells or HeLa cells with stable overexpression or knockdown of PLCE1, corresponding plasmids and their controls (empty vector or vector containing scrambled shRNA) were amplified in 293T cells, followed by infecting them to KYSE510, KYSE150, KYSE30 and HeLa cells, respectively. KYSE510 and KYSE150 cells overexpressing PLCE1 were selected with G418, while KYSE30 and HeLa cells with knockdown of PLCE1 were selected with puromycin.
Western blot assays
Protein extracts from cells were prepared using detergent lysis buffer. Total protein (60 µg) was subjected to SDS-polyacrylamide gel electrophoresis and transferred to PVDF membrane (Millipore). Antibody against PLCε1 (Abnova, PAB20820), OCT2 (Abcam, ab33919) or β-ACTIN (SantaCruz, sc-47778) was used. The membranes were incubated overnight at 4°C with the primary antibody (1:1000) and the proteins were detected with a Phototope-Horseradish Peroxidase Western Blot Detection kit (Thermo Fisher).
Cell viability and colony formation assays
Cells were seeded in 96-well flat-bottomed plates and each well contained 2000 cells in 100 μl cell suspension. After a certain time of cultivation, cell viability was measured using the CCK-8 Kit (Dojindo, Japan). Each experiment having six replicates was repeated three times. For colony formation assay, 2000 cells were seeded in 65-mm culture dishes and allowed to grow until visible colonies formed in complete growth media (2 weeks). Cell colonies were fixed with methanol, stained with crystal violet and counted.
Xenograft growth of cancer cells in mice
BALB/c nude mice, aged 4−5 weeks, purchased from HFK Bioscience (Beijing), were acclimatized to local conditions for one week and then maintained under a 12-h dark, 12 h light cycle with food and water ad libitum. Animals (five mice in each group) were injected subcutaneously with 0.1 ml of cell suspension containing 2 × 10 5 cells into the back flank. When a tumor was palpable, its volume was measured every other day and calculated according to the formula, Volume = Length × Width 2 × 0.5.
All the experiments were performed in accordance with relevant institutional and national guidelines and regulations.
Histological and immunohistochemical analysis
Formalin-fixed, paraffin-embedded tumor samples were sectioned, stained with hematoxylin and eosin and analyzed under light microscopy. For immunohistochemical staining of PLCε1 and Ki-67, rabbit antibody against PLCε1 (1:100) or Ki-67 (1:50, Santa-Cruz, sc-15402) was incubated with the tissue sections at 4 o C overnight and then detected with the ABC kit (Pierce).
Statistical analysis
The association between SNPs and ESCC risk was analyzed by an additive model in a logistic regression framework with age, sex, smoking status and drinking status as covariates. For the functional analysis, results were presented by using mean ± SEM; the comparison of mean between two groups was conducted by using Student-t test. Data in abnormal distribution were analyzed by nonparametric test. All statistical analyses for the functional analysis were performed using SPSS (version 20.0, SPSS Inc.).
Results
Fine mapping and functional analysis of PLCE1 non-coding variants
We imputed the PLCE1 gene region (chr10:95743746-96098148, hg19) using our previous GWAS data of 2031 cases with ESCC and 2044 controls (4). After imputation, there were 590 (80 directly genotyped and 510 well-imputed) SNPs in the PLCE1 gene region and among them, 33 SNPs were significantly associated with ESCC risk in addition to the GWAS-reported rs2274223 (all P < 1 × 10 -6 ; Supplementary Table 7 , available at Carcinogenesis Online). All these 34 associated variants are in the same linkage disequilibrium block ( Figure 1 ) and 32 are in the non-coding regions (26 in intron and 6 in downstream) while 2 are in the coding region of PLCE1 (Supplementary Table 8 , available at Carcinogenesis Online). Since variants in the non-coding region might be implicated in gene expression regulation, we then performed in silico functional annotation based on the HaploReg database (11) and found that the variants rs71031566[C----/ CATTT] in intron 22 and rs12220125[T/G] in intron 28 reside within the regions that are rich in H3K4me1 and hypersensitive to DNase (Supplementary Table 8 , available at Carcinogenesis Online), the markers of regulatory DNA region. Annotation by ENCODE database also suggested that these two variants are within the potential regulatory regions (Figure 2A ). We then performed reporter gene assays using pGL4.10-E4TATA firefly luciferase expression vector with allele-different fragments of PLCE1 harboring rs71031566 or rs12220125 ( Figure 2B and C) and the results showed significant difference between rs71031566[C----] and rs71031566[CATTT] alleles in driving reporter gene expression ( Figure 2D) ; however, no such difference was seen between rs12220125[T] and rs12220125[G] alleles ( Figure 2E ). These results indicate that the region harboring rs71031566 is likely to have regulatory function while the region harboring rs12220125 may not be functionally relevant.
Validation of the association between rs71031566 variant and ESCC risk
In our previous genome-wide screening (4), the rs71031566 ). We then replicated this indel variation in an additional sample set consisting of 1782 cases and 2352 controls and the results showed that it was also significantly associated with risk of ESCC in the same direction as in the genome-wide scan stage, with the OR of 1.25 (95% CI = 1.12-1.40; P = 1.12 × 10 -4 ). In combined sample of genomewide scan and replication, the rs71031566[C----/CATTT] variant was associated with 1.28-fold increased risk of developing ESCC (95% CI = 1.19-1.38; P = 1.59 × 10 −10
; Table 1 ).
Variant rs71031566 impairs PLCE1 transcription by a long-range regulation mechanism
We next examined whether the DNA fragment in intron 22 where rs71031566 resides has regulatory activity as enhancer or silencer towards PLCE1 expression and whether the rs71031566[C----] and rs71031566[CATTT] alleles have different function. We replaced the E4TATA of pGL4.10-E4TATA reporter gene construct with PLCE1 promoter ( Figure 3A ) and the reporter gene assays showed that the construct containing the fragment with the rs71031566[CATTT] allele, regardless of the 5ʹ or 3ʹ direction of the DNA, had significantly lower luciferase expression than the construct containing the fragment with the rs71031566[C----] allele in both KYSE150 and KYSE30 cells ( Figure 3B and D) , suggesting that the ATTT insertion might create a silencer. Since rs71031566 site is about 250-kb away from PLCE1 transcription start site and might exist a physical contact between the DNA region harboring rs71031566 variant in intron 22 and the PLCE1 promoter, we therefore performed chromosome conformation capture assays. The results showed that in RKO, KYSE30, BxPC-3 cells carrying the rs71031566[CATTT/ CATTT] genotype, there was a strong signal for cross-linking between intron 22 and the PLCE1 promoter (position −3106 to −2800); however, in other cells carrying the rs71031566 [C----/C----] genotype, the signal was much weaker ( Figure 3C ). These results suggest that rs71031566[CATTT] might repress PLCE1 expression through a long-range regulation. with P < 1 × 10 -6 are above the black horizontal line and the smallest P value of rs7094783 is 3.13 × 10 -9 . Axes: y-axis indicates the -log 10 P values; x-axis shows genomic position of SNPs based on NCBI build 37. The LD plot is based on the genotypes after imputation in the discovery stage.
Repression of PLCE1 expression by rs71031566[CATTT] is mediated by OCT2
The rs71031566[CATTT] insertion variant might repress PLCE1 expression as a silencer ( Figure 4A ) and in silico analysis using three public databases, HaploReg (11), JASPAR (12) and AliBaba2 (13), consistently suggested that rs71031566[CATTT] insertion may create an element for OCT2 binding in this DNA region. We then carried out electrophoretic mobility shift assays and found a DNA-protein complex when the DNA fragment containing the rs71031566[CATTT] was incubated with nuclear proteins; however, no such a complex occurred when the DNA containing rs71031566[C----] was incubated with nuclear extracts ( Figure 4B , 
Lanes 2 and 7)
. This DNA-protein complex could be eliminated by the addition of non-labeled DNA containing rs71031566 [CATTT] but not that containing rs71031566[C----] ( Figure 4B , Lanes 3−5). Moreover, a clear super-shift band of the DNA-protein complex was seen when a specific antibody against OCT2 was included in the incubation mixture ( Figure 4C , Lane 3), suggesting that the protein bound to the DNA is likely OCT2. To examine whether this allele-specific OCT2 binding occurs in vivo in cells, we performed ChIP-qPCR assays. Five fragments centered on rs71031566 in intron 22 (I1−I5) and 12 fragments (P1−P12) centered on the cross-linking peak identified by chromosome conformation capture assays in the PLCE1 promoter region (position −3817 to −1778) were tested ( Figure 4D 
PLCE1 mRNA expression in human esophageal tissue samples
We found that PLCE1 mRNA levels were significantly lower in ESCC than those in their paired normal tissues in two independent sets of clinical samples (N = 80, P = 0.003 and N = 88, P < 0.001; Figure 5A and B) consistent with the previous findings reported in Oncomine ( Figure 5C ). By examination of DNA sequencing data (14), we found neither copy number change nor somatic mutations of PLCE1 in ESCC, indicating that aberrant expression might be the major underlying mechanism for PLCE1 to implicate in the development of ESCC. We further found that individuals with the rs71031566[CATTT/CATTT] genotype expressed significantly lower PLCE1 mRNA and protein levels in ESCC samples compared with those with the rs71031566[C----/ CATTT] or rs71031566[C----/C----] genotype ( Figure 5D and E), indirectly indicating a variant-specific effect of PLCE1 in vivo.
Effect of PLCE1 on ESCC cell proliferation
We next examined the effect of aberrant PLCE1 expression on cell malignant phenotypes in vitro and in vivo. We found that Figure 2C , available at Carcinogenesis Online) while overexpression of PLCE1 not only declined xenograft growth but also reduced the incidence of tumor formation (40% versus 100% in both KYSE510 and KYSE150 cell lines; Figure 6F and Supplementary Figure 2D , available at Carcinogenesis Online). Immunohistochemical staining showed that the number of Ki-67-positive cells was remarkably reduced in xenografts with PLCE1 overexpression compared with xenografts without PLCE1 overexpression (Supplementary Figure 2E , available at Carcinogenesis Online).
Discussion
Previous GWAS on ESCC have consistently identified PLCE1 as a susceptibility locus in Chinese populations (2) (3) (4) (5) . By imputation and independent verification, we further identified a PLCE1 The role of PLCE1 in the development of cancer remains contradictory. Some studies have suggested it as a tumor promoter (2, (15) (16) (17) but others proposed it as a tumor suppressor (18) (19) (20) (21) (22) (23) (24) . For example, in mice treated with a chemical carcinogen, tumor formation was significantly reduced in those with plce knockout, suggesting a tumor promoter function of plce (15) ; however, in ultraviolet B-induced (19) or ras-driven (20) mouse skin cancer model, knockout of plce significantly increased tumor production, indicating a tumor suppressor role of this gene. Although the reason for this discrepancy has not been clarified, it might be related to the experimental models used in the different studies. In human ESCC, one group showed higher expression of PLCE1 mRNA and protein in tumor tissues compared with adjacent normal tissues and upregulation of PLCE1 was correlated with advanced tumor stage and lymph node metastasis (17, (25) (26) (27) ; knockdown of PLCE1 promoted apoptosis and sensitivity to chemotherapeutic drugs but abrogated the proliferation and epithelial-mesenchymal transition phenotype in ESCC cells in vitro (17) . However, other groups reported completely opposite results. 96-well plates transfected with PLCE1, PLCE1-shRNA or control lentivirus vector was determined daily for 4 days by CCK-8 assay. For proliferation, the results represent mean ± s.e.m. from three experiments and each experiment had six replicates; **P < 0.01 compared with control. For colony formation, the results represent colony formation ability relative to control set to 100% from three experiments; *P < 0.05; **P < 0.01 and ***P < 0.001 compared with each control. (E, F) Effect of PLCE1 knockdown or overexpression on xenograft tumor formation and growth in nude mice. Results are mean ± s.e.m. from five animals in each group. *P < 0.05; **P < 0.01 and ***P < 0.001 compared with control.
For instance, Li et al. showed significantly reduced PLCE1 mRNA and non-significantly reduced protein expression in ESCC compared with normal tissues and a positive association between longer survivals in ESCC patients and increased tumor-normal mRNA or protein fold change (24) . Hu et al. (23) also reported a significant reduction of PLCE1 mRNA in ESCC compared with normal tissues. Our results in the present study demonstrated that PLCE1 is down-regulated in the majority of ESCC compared with paired non-tumor tissues. These results are in line with and strongly support the notion that PLCE1 may function as a tumor suppressor in the development of ESCC. This conclusion is also logical and biological plausible in view of the fact that PKC, the downstream molecule of PLCε1, has recently been identified as a bona fide tumor suppressor (28) .
In the present study, we have shown that susceptibility to ESCC of rs71031566[CATTT] allele may be due to repressing PLCE1 expression by this insertion element through a longrange regulatory mechanism and confirmed an allele-specific interaction between this polymorphic region and the PLCE1 promoter in a native chromatin context in vivo in cells. Longrange interaction such as enhancer (silencer)-promoter interaction plays an important role in gene expression regulation. For instance, several studies have reported that non-coding SNPs associated with a certain phenotype identified by GWAS can be in enhancer or silencer elements regulating transcription of a target gene (29) (30) (31) . We found that the interaction between the polymorphic region in intron 22 and the promoter of PLCE1 is most likely mediated by OCT2, a member of the POU domain family of transcriptional regulators. It has been shown that OCT2 can function as an activator or repressor of transcription depending on the cell type (32) . In line with our results, a recent study reported that OCT2 can repress iNOS transcription by interfering with recruitment of RNA PoIII by OCT1 (33) . Further studies are warranted to characterize in more detail the transcriptional complex underlying the long-range regulation of PLCE1 expression by repressive element (silencer). rs71031566 C----/CATTT variation also locates in the 5'UTR of PLCE1-AS1 (143 bp upstream), a gene encodes a 1370 bp antisense RNA of PLCE1. One may argue that the associated of ESCC risk with this genetic variation might be mediated by PLCE1-AS1 but not PLCE1 itself. We analyzed the expression levels of PLCE1-AS1 mRNA in both ESCC and paired non-tumor tissue specimens and found that the levels were very lower and 70% of samples (N = 94) had a level below the detection limit of both RT-qPCR and RNA sequencing. Furthermore, no significant differences in the mRNA levels between normal and tumor tissues were seen (data not shown). These results suggest that PLCE1-AS1 might not be important in ESCC. More importantly, we did not found any significant differences in the mRNA levels of PLCE1-AS1 as function of rs71031566 genotypes, suggesting that the mRNA expression of PLCE1-AS1 may not be affected by the genetic variation, suggesting that it is PLCE1 but not PLCE1-AS1 that contributes to ESCC susceptibility.
In conclusion, we have demonstrated in this study for the first time that an intronic four-nucleotide insertion polymorphism in PLCE1 may create a silencer, which can interact in long-range with the PLCE1 promoter mediated by OCT2 and impairs the gene transcription. The attenuated expression of PLCE1 due to the genetic variant may weaken its tumor suppressor function, which may be the underlying mechanism for those with the variant genotype to be susceptible to the development of ESCC.
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